BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
144.1 ^USD	+3.69%		+9.30%	-20.09%

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Beigene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia

April 28, 2022 at 07:00 am EDT

BeiGene announced that the BTK inhibitor BRUKINSA (zanubrutinib) has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström's macroglobulinemia. BeiGene and Adium entered into an exclusive distribution agreement for Adium to commercialize BRUKINSA in Latin America.

Latest news about BeiGene, Ltd.

Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23	MT
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	Apr. 23	DJ
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23	MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	Apr. 23	MT
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	CI
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10	MT
Beigene Shrinks Loss by 56% in 2023	Mar. 29	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22	MT
BeiGene, Ltd. Announces Executive Changes	Mar. 20	CI
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15	MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing	Mar. 14	MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients	Mar. 14	DJ
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	Mar. 14	MT
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	CI
US FDA approves BeiGene's esophageal cancer therapy	Mar. 14	RE
BeiGene Sells Over 1 Million Underlying Shares Under Purchase Plan	Mar. 14	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	Mar. 13	MT
BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership	Mar. 13	MT
BeiGene Shares Rise on First Dosing of Brukinsa	Mar. 13	DJ
BeiGene Gets FDA's Accelerated Approval for Follicular Lymphoma Treatment	Mar. 07	MT

Chart BeiGene, Ltd.

Duration

Period

More charts

Company Profile

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BeiGene, Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

144.1 USD

Average target price

268.7 USD

Spread / Average Target

+86.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BEIGENE, LTD.	-20.09%	15.06B
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B
LEGEND BIOTECH CORPORATION	-24.93%	8.22B

Bio Therapeutic Drugs